Citigroup
KYMR icon

Citigroup’s Kymera Therapeutics KYMR Stock Holding History

Citigroup’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.2M Buy
126,813
+49,029
+63% +$5.62M ﹤0.01% 1399
2026
Q2 		$8.92M Buy
77,784
+65,520
+534% +$5.63M ﹤0.01% 1703
2026
Q1 		$1.02M Buy
12,264
+1,757
+17% +$139K ﹤0.01% 3104
2025
Q4 		$818K Buy
10,507
+3,601
+52% +$243K ﹤0.01% 3262
2025
Q3 		$391K Sell
6,906
-21,775
-76% -$982K ﹤0.01% 3695
2025
Q2 		$1.25M Sell
28,681
-52,391
-65% -$1.8M ﹤0.01% 3039
2025
Q1 		$2.22M Buy
81,072
+16,656
+26% +$607K ﹤0.01% 2605
2024
Q4 		$2.59M Buy
64,416
+29,852
+86% +$1.35M ﹤0.01% 2596
2024
Q3 		$1.64M Buy
34,564
+14,978
+76% +$661K ﹤0.01% 2840
2024
Q2 		$585K Sell
19,586
-201,325
-91% -$6.97M ﹤0.01% 3289
2024
Q1 		$8.88M Buy
220,911
+131,982
+148% +$4.72M 0.01% 1323
2023
Q4 		$2.26M Sell
88,929
-11,867
-12% -$212K ﹤0.01% 2136
2023
Q3 		$1.4M Sell
100,796
-7,772
-7% -$156K ﹤0.01% 2259
2023
Q2 		$2.5M Sell
108,568
-96,163
-47% -$2.76M ﹤0.01% 2006
2023
Q1 		$6.07M Buy
204,731
+72,647
+55% +$2.34M ﹤0.01% 1396
2022
Q4 		$3.3M Sell
132,084
-68,956
-34% -$1.84M ﹤0.01% 1715
2022
Q3 		$4.38M Buy
201,040
+10,239
+5% +$270K ﹤0.01% 1626
2022
Q2 		$3.76M Buy
190,801
+169,002
+775% +$3.95M ﹤0.01% 1697
2022
Q1 		$923K Sell
21,799
-59,852
-73% -$2.53M ﹤0.01% 3048
2021
Q4 		$5.18M Buy
81,651
+28,313
+53% +$1.65M ﹤0.01% 1803
2021
Q3 		$3.13M Sell
53,338
-30,127
-36% -$1.75M ﹤0.01% 2152
2021
Q2 		$4.05M Buy
83,465
+19,780
+31% +$859K ﹤0.01% 2082
2021
Q1 		$2.48M Buy
63,685
+61,653
+3,034% +$3.71M ﹤0.01% 2358
2020
Q4 		$126K Buy
+2,032
New +$99.1K ﹤0.01% 5351

Other funds holding KYMR

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return
Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $29.2B AUM 30.02% 1-Year Est. Return

Citigroup's KYMR Position: Q3 2026 in Review

Citigroup increased its Kymera Therapeutics (KYMR) stake by 63% in Q3 2026, buying an estimated $5.62M and bringing the position to 126,813 shares worth $14.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1399.

Citigroup first reported a position in KYMR in Q4 2020 and has held it in 24 quarters since. 80 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • Citigroup held 126,813 shares of Kymera Therapeutics worth $14.2M as of Q3 2026.
  • Citigroup bought 49,029 Kymera Therapeutics shares in Q3 2026, an estimated $5.62M.
  • Kymera Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #1399 holding.
  • Citigroup first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 24 quarters since.
  • 80 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.